Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Ngā kaituhi matua: Ju Li (Author), Zhongyuan Zhang (Author), Xinhua Wu (Author), Jie Zhou (Author), Deqian Meng (Author), Ping Zhu (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...